Articles Published in 2011

APEPTICO successfully completes phase I AP301 trial

Tuesday, October 25, 2011 11:19 AM

APEPTICO has completed a phase I clinical trial for its pulmonary sodium ion channel activator AP301. The orally inhaled drug candidate was safe and well-tolerated by all study participants. AP301 is being developed for the prevention and treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation.

More... »

NERI receives $45 million grant to support Pediatric Heart Network

Tuesday, October 25, 2011 10:44 AM

New England Research Institutes (NERI) has received a $45 million grant from the National Institutes of Health (NIH) for the continuance of its work on the Pediatric Heart Network (PHN). PHN is a multi-center clinical research network started in 2001, supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, to study congenital and acquired heart diseases that occur in childhood. This grant provides five more years of funding to nine clinical centers and NERI as the data coordinating center, to conduct clinical research studies in children and young adults with heart defects and other heart diseases.

More... »

Metabolomx awarded $1.14 million grant from NCI

Monday, October 24, 2011 01:34 PM

Metabolomx, a diagnostic company focused on breath analysis for the detection of cancer, has been awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI). The $1.14 million combined phase I/II Fast-Track contract will support the research and development of Metabolomx' sensor array system to detect lung cancer.

More... »

Sanofi names Meeker CEO of Genzyme

Monday, October 24, 2011 01:18 PM

Sanofi has named David Meeker as chief executive officer of Genzyme, a Sanofi company, effective November 1, 2011. He will report to Christopher A. Viehbacher, chief executive officer of Sanofi, and will join the group management committee. Viehbacher will retain the position of chairman, Genzyme.

More... »

Cubist acquires Adolor in an agreement worth $415 million

Monday, October 24, 2011 01:00 PM

Cubist Pharmaceuticals and Adolor have signed a definitive agreement under which Cubist will acquire all of the outstanding shares of Adolor for approximately $190 million on a fully-diluted basis, net of Adolor's third quarter 2011 cash balance. The total transaction is valued at up to $415 million, net of Adolor's third quarter 2011 cash balance, and is expected to be accretive in 2012.

More... »

WuXi PharmaTech acquires two clinical research companies in China

Monday, October 24, 2011 11:44 AM

WuXi PharmaTech has acquired MedKey Med-Tech Development and Jiecheng Med-Tech Development, two related contract clinical research services companies based in Shanghai, China. The financial terms of the transaction were not disclosed.

More... »

ShangPharma acquires Charles River’s Shanghai facility

Monday, October 24, 2011 10:49 AM

ShangPharma, a China-based pharmaceutical and biotechnology research and development outsourcing company, has acquired the assets in Charles River Laboratories International’s Shanghai research facility.

More... »

CenterWatch, Plutus Capital launch Clinical Trials Quarterly

Monday, October 24, 2011 10:37 AM

CenterWatch and Plutus Capital Partners have launched Clinical Trials Quarterly, a co-branded newsletter for the contract research organization (CRO) industry that expands CenterWatch’s reach to financial clients in Asia and Europe.

More... »

Goodwin Biotech collaborates with Spectros

Monday, October 24, 2011 10:31 AM

Goodwin Biotechnology and Spectros have reported a collaboration for the process development and cGMP manufacturing of an antibody: dye conjugate that will be used in phase I and phase II clinical trials.

More... »

Survey: Top CROs doubled workforce over past decade

Monday, October 24, 2011 08:02 AM

Over the last 10 years, the top nine global CROs have more than doubled their workforce, which now exceeds 72,000 employees, and their revenues have increased at a compound annualized rate of 11% as they increasingly play a larger and more integral role in the drug development infrastructure, according to a new Association of Clinical Research Organizations (ACRO) member survey.

More... »